MedPath

Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts

Phase 4
Completed
Conditions
Plantar Wart
Common Wart
Interventions
Drug: Measles-Mumps-Rubella Vaccine
Procedure: cryotherapy
Registration Number
NCT03183765
Lead Sponsor
Assiut University
Brief Summary

Warts are benign epidermal tumors caused by human papilloma virus, which are epitheliotropic non-enveloped double stranded DNA viruses. Transmission of warts occurs from direct person-to-person contact or indirectly by fomites . Warts appear in various forms including verruca vulgaris, plane, plantar, filiform, digitate and periungual.

Detailed Description

Treatment of warts is difficult for patients and physicians . Currently Available treatment options include cryosurgery, laser, electrosurgery, bleomycin, and topical keratolytic applications; many of them are painful, ineffective, costly and prone for recurrences.

Cryotherapy, which uses liquid nitrogen to freeze tissues and destroy warts, is one of the most common and effective treatments. freezing causes local irritation, leading the host to mount an immune reaction against the virus.

Immunotherapy appears to enhance virus recognition by immune system; allowing clearance of treated wart, distant warts , and helps to prevent infection .Recently, intralesional immunotherapy using different antigens such as mumps, Candida, and tuberculin has been proved effective in the treatment of warts.

The exact mechanism of action of intralesional immunotherapy is still obscure. Intralesional antigen injection probably induces strong non specific inflammatory response against the human papilloma virus-infected cells.

It has been suggested that intralesional measles mumps rubella vaccine results in regression of warts via induction of immune system.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Patients should have multiple common or plantar warts.
  • No concurrent systemic or topical treatment of warts
Read More
Exclusion Criteria
  • patients under 16 years old.

    • Patients with fever or signs of any inflammation or infection.

  • Patients with other types of warts.

  • Patients with single warts.

    • Pregnancy.
    • Lactation.
    • Immunosuppression.
    • Patients who received any other treatments for their warts in the month before starting study.
    • Past history of asthma, allergic skin disorders, meningitis or convulsions.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MMR vaccineMeasles-Mumps-Rubella VaccineMeasles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
Cryotherapycryotherapypatients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
Primary Outcome Measures
NameTimeMethod
Cure rate60 days

Assess cure rate of MMR vaccine and cryotherapy in treatment of common and planter warts (complete disappearance of lesions) one month after last session, compare efficacy of both measures.

Secondary Outcome Measures
NameTimeMethod
Detection of partial response to both measures60 days

if there was a decrease in the size or a decrease in the total number of warts

Side effects60 days

Detection of post procedure side effects such as flu like symptoms, pain , hypopigmentation.

Trial Locations

Locations (1)

Assiut university hospitals

🇪🇬

Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath